Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
Heart-1 Clinical Trial of VERVE-101 Ongoing with Initial Data Expected in the Second Half of 2023 VERVE-102 Named Second PCSK9-Targeting Program, Leveraging Novel GalNAc-LNP Delivery with Clinical... | May 15, 2023
Source: marketscreener.com